Avlayah (tividenofusp alfa-eknm) Coverage Criteria
Customize your policy alerts
Sign up for Empire Bluecross Policy CC-0302 alerts
Get alerted when Policy CC-0302 changes without checking for updates manually.
Monitor payer policy activity
Medical-necessity and prior-authorization review for Avlayah in pediatric individuals with neurologic manifestations of Mucopolysaccharidosis II (Hunter syndrome), including initial and continuation therapy, quantity limits, and coding.
HCPCS codes C9399 and J3590 were removed from the policy effective September 30, 2026.
HCPCS code J1757 was added effective October 1, 2026 for injection of tividenofusp alfa-eknm.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.